NCT03510598View on ClinicalTrials.gov

Submental Study (Sequential Treatment Approach)

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 27, 2018

Primary Completion Date

December 8, 2018

Study Completion Date

December 8, 2018

Conditions
Body Fat Disorder
Interventions
DEVICE

The ZELTIQ CoolSculpting System

The CoolSculpting machine will be used to perform the treatments.

DRUG

Kybella 20 MG in 2 ML Injection

Injectable drug called KYBELLA® (deoxycholic acid)

Trial Locations (1)

90004

Rebecca Fitzgerald, MD Dermatology, Los Angeles

All Listed Sponsors
lead

Zeltiq Aesthetics

INDUSTRY

NCT03510598 - Submental Study (Sequential Treatment Approach) | Biotech Hunter | Biotech Hunter